226085-18-3

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]-;3-broMo-1-tosyl-1H-pyrrolo[2,3-b]pyridine;3-broMo-1-(4-Methylsulfonyl)-7-azaindole;3-broMo-1-[(4-Methylbenzene)sulfonyl]-1H-pyrrolo[2,3-b]pyridine;3-broMo-1-tosyl-1H-pyrrolo[2;3-bromo-1-p-tosyl-1H-pyrro[2,3-b]pyridine
• CAS NO: 226085-18-3
• Molecular Formula: C₁₄H₁₁BrN₂O₂S
• Molecular Weight: 351.23
• Mol File: 226085-18-3.mol

Chemical Properties

• Boiling Point: 514.893°C at 760 mmHg
• Flash Point: 265.198°C
• Appearance: /
• Density: 1.597g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: 2-8°C
• PKA: -0.12±0.30(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]-(226085-18-3)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]-(226085-18-3)

Safety Data

• Hazardous Substances Data: 226085-18-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]is used as a building block in the synthesis of various biologically active compounds for pharmaceutical research. Its unique structure and chemical reactivity contribute to the development of new drug molecules with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Pyrrolo[2,3-b]pyridine, 3-bromo-1-[(4-methylphenyl)sulfonyl]serves as a key intermediate for the creation of complex organic molecules. Its presence of a bromine atom and sulfonyl group allows for further functionalization and modification, expanding the scope of synthetic applications.
Note: Since the provided materials do not specify different industries or detailed application reasons, the uses are generalized based on the information given. If more specific applications or industries are identified in future research, they can be added accordingly.

InChI:InChI=1/C14H11BrN2O2S/c1-10-4-6-11(7-5-10)20(18,19)17-9-13(15)12-3-2-8-16-14(12)17/h2-9H,1H3

Upstream product

• 74420-15-8 3-bromo-1H-pyrrolo[2,3-b]pyridine 
• 98-59-9 p-toluenesulfonyl chloride 
• 271-63-6 7-Azaindole 
• 348640-02-8 1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 866545-95-1 3-(2-chloropyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 866545-91-7 1-(4-methylbenzenesulfonyl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1417421-80-7 (R)-2-methyl-2-(2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)butanoic acid 
• 944842-54-0 decernotinib 
• 1417421-95-4 methyl 2-methyl-2-((2-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)butanoate 
• 1417421-89-6 C₂₁⁽¹³⁾C₄H₂₅F₃N₄⁽¹⁵⁾N₂O₃S 
• 882562-39-2 1-(4-methylbenzenesulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-ylboronic acid 
• 866545-92-8 3-(2-(methylthio)pyrimidin-4-yl)-1-(tolyl-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 866545-93-9 3-(2-(methylsulfonyl)pyrimidin-4-yl)-1-(tolyl-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1052631-05-6 C₂₅H₂₁N₅O₂S 
• 1052629-04-5 C₂₅H₂₁N₅O₂S 

Relevant articles and documents

Azaindole derivative containing aza amino acid as well as preparation and application thereof

The invention provides an azaindole derivative containing aza amino acid as well as preparation and application thereof. The compound has a good inhibition effect on influenza viruses in vitro, IC50 and EC50 in anti-influenza virus polymerase and anti-inf

Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents

A class of 3-substituted 1H-pyrrolo[2,3-b]pyridine derivatives were designed, synthesized and evaluated for their in vitro biological activities against maternal embryonic leucine zipper kinase (MELK). Among these derivatives, the optimized compound 16h e

Discovery of a novel class of covalent dual inhibitors targeting the protein kinases bmx and btk

The nonreceptor tyrosine TEC kinases are key regulators of the immune system and play a crucial role in the pathogenesis of diverse hematological malignancies. In contrast to the substantial efforts in inhibitor development for Bruton’s tyrosine kinase (BTK), specific inhibitors of the other TEC kinases, including the bone marrow tyrosine kinase on chromosome X (BMX), remain sparse. Here we present a novel class of dual BMX/BTK inhibitors, which were designed from irreversible inhibitors of Janus kinase (JAK) 3 targeting a cysteine located within the solvent-exposed front region of the ATP binding pocket. Structure-guided design exploiting the differences in the gatekeeper residues enabled the achievement of high selectivity over JAK3 and certain other kinases harboring a sterically demanding residue at this position. The most active compounds inhibited BMX and BTK with apparent IC50 values in the single digit nanomolar range or below showing moderate selectivity within the TEC family and potent cellular target engagement. These compounds represent an important first step towards selective chemical probes for the protein kinase BMX.

Synthesis of Differentially Protected Azatryptophan Analogs via Pd2(dba)3/XPhos Catalyzed Negishi Coupling of N-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected tert-Butyl (R)-2-Amino-3-iodopropanoate

Unnatural amino acids play an important role in peptide based drug discovery. Herein, we report a class of differentially protected azatryptophan derivatives synthesized from N-tosyl-3-haloazaindoles 1 and Fmoc-protected tert-butyl iodoalanine 2 via a Neg

Catalytic Asymmetric Synthesis of α-Arylpyrrolidines and Benzo-fused Nitrogen Heterocycles

Herein, we report a practical two-step synthetic route to α-arylpyrrolidines through Suzuki–Miyaura cross-coupling and enantioselective copper-catalyzed intramolecular hydroamination reactions. The excellent stereoselectivity and broad scope for the transformation of substrates with pharmaceutically relevant heteroarenes render this method a practical and versatile approach for pyrrolidine synthesis. Additionally, this intramolecular hydroamination strategy facilitates the asymmetric synthesis of tetrahydroisoquinolines and medium-ring dibenzo-fused nitrogen heterocycles.

DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES

The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4,

Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design

Current treatment of toxoplasmosis targets the parasite’s folate metabolism through inhibition of dihydrofolate reductase (DHFR). The most widely used DHFR antagonist, pyrimethamine, was introduced over 60 years ago and is associated with toxicity that can be largely attributed to a similar affinity for parasite and human DHFR. Computational analysis of biochemical differences between Toxoplasma gondii and human DHFR enabled the design of inhibitors with both improved potency and selectivity. The approach described herein yielded TRC-19, a promising lead with an IC50 of 9 nM and 89-fold selectivity in favor of Toxoplasma gondii DHFR, as well as crystallographic data to substantiate in silico methodology. Overall, 50% of synthesized in silico designs met hit threshold criteria of IC50 2-fold selectivity favoring Toxoplasma gondii, further demonstrating the efficiency of our structure-based drug design approach.

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (Ki) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.

COMPOUND, ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE

The present invention relates to a compound, and an organic optoelectronic element and a display device including the same wherein the compound denoted by chemical formula 1 is provided. In chemical formula 1, X1 to X10, L, n and R11 are as defined in the